CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon

Patients with cholangiocarcinoma have poor clinical outcomes due to late diagnoses, poor prognoses, and limited treatment strategies. To identify drug combinations for this disease, we have conducted a genome-wide CRISPR screen anchored on the bromodomain and extraterminal domain (BET) PROTAC degrad...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	JCI Insight
المؤلفون الرئيسيون:	Yan Zhu, Dengyong Zhang, Pooja Shukla, Young-Ho Jung, Prit Benny Malgulwar, Sharmeen Chagani, Medina Colic, Sarah Benjamin, John A. Copland III, Lin Tan, Philip L. Lorenzi, Milind Javle, Jason T. Huse, Jason Roszik, Traver Hart, Lawrence N. Kwong
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	American Society for Clinical investigation 2024-01-01
الموضوعات:	Cell biology Gastroenterology
الوصول للمادة أونلاين:	https://doi.org/10.1172/jci.insight.174220